Novo Ventures co-leads US $83m series C financing in Lava Therapeutics

New investment to support advancement of powerful bispecific Gamma-Delta T cell engager programs for the treatment of a broad range of cancers Leading global life sciences venture has invested approx US$1 billion in last two years COPENHAGEN, Denmark... Biopharmaceuticals, Oncology, Venture Capital Novo Ventures, LAVA Therapeutics, gamma-delta T cells
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news